Da den systemiske eksponering hos ikke- gravide kvinder er ubetydelig efter behandling med NEVANAC, kunne risikoen anses for lav under graviditet.
Since the systemic exposure in non-pregnant women is negligible after treatment with NEVANAC, the risk during pregnancy could be considered low.